


# Augmentin™



**Enduring trust**

## The journey of Augmentin: key milestones

# Augmentin™



### References:

1. Rolinson GN. Historical perspective: Forty years of beta-lactam research. *Journal of Antimicrobial Chemotherapy*; 1998; 41, 589-603.
2. Geddes AM, Klugman KP, Rolinson GN. Introduction: historical perspective and development of amoxicillin/clavulanate. *International Journal of Antimicrobial Agents* 30S (2007) S109-S112.
3. White AR, Kaye C, Poupart J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community acquired respiratory tract infection: a review of continuing development of an innovative antimicrobial agent. *Journal of Antimicrobial Chemotherapy* (2004), 53, Suppl. S1 i3-i20.
4. Felmingham D, White AR, Jacobs MR, Appelbaum PC, Poupart J, Miller LA, Gruneberg RN. The Alexander Project: the benefits from a decade of surveillance. *Journal of Antimicrobial Chemotherapy*, 2005, 56, Suppl. S2: ii3-ii21.
5. Kaye CM, Allen A, Perry S, McDonagh M, Davy M, Storm K, Bird N, Dewit O. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of Amoxicillin/Clavulanate. *Clinical Therapeutics*. 2001, 23(4): 578-584.
6. Klein J O. Amoxicillin/Clavulanate for infections in infants and children: past, present and future. *Pediatr Infect Dis J*, 2003; 22: S139-48.
7. Sener B et al. A survey of antibiotic resistance in *Streptococcus pneumoniae* and *Haemophilus influenzae* in Turkey, 2004-2005. *Journal of Antimicrobial Chemotherapy*. 2007, 60: 587-593.
8. Bryan J. Still going strong at 30: co-amoxiclav. *The Pharmaceutical Journal*. Vol. 286, June 2011: 762-63.

● **Main Augmentin Safety Statement:**

- Contraindicated in patients with known hypersensitivity to beta-lactam antibiotics (penicillins and cephalosporins)
- Gastrointestinal disturbances are common
- Prolonged use may result in overgrowth of non-susceptible organisms
- Contraindicated in patients with history of jaundice/hepatic impairment due to amoxycilin/clavulanic acid treatment.

[www.hcp.gsk.co.il](http://www.hcp.gsk.co.il)

הירך מוחמן להיכנס לאתר



**GlaxoSmithKline.** 25 Basel street, P.O. Box 10283,  
Petach-Tikva 4900202 Israel, Tel: 03-9297100.

**Medical information service:** il.medinfo@gsk.com

**Adverse events reporting service:** il.safety@gsk.com,  
Tel: 03-9297100

ל-PI המלא נא ללחוץ כאן